Lakefront Biotherapeutics (LKFT) Net Income towards Common Stockholders Growth (1y) (2015 - 2026)
Powered by 
Analysis
Lakefront Biotherapeutics (LKFT) Net Income towards Common Stockholders Growth (1y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 6.48% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -6.81% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 92.37% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.21% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 151.28% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 327.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -12.04% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 95.87% |
| 10 | Lakefront Biotherapeutics | 1.88 Bn | 1.88 Bn | 3.51 Mn | -128.49% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -128.49% |
| Mar 31, 2026 | 110.51% |
| Dec 31, 2025 | 372.83% |
| Sep 30, 2025 | -447.41% |
| Jun 30, 2025 | 207.50% |
| Mar 31, 2025 | -264.64% |
| Dec 31, 2024 | -65.26% |
| Sep 30, 2024 | -201.45% |
| Jun 30, 2024 | 8,954.39% |
| Mar 31, 2024 | 293.48% |
| Dec 31, 2023 | 97,461.30% |
| Sep 30, 2023 | -262.48% |
| Jun 30, 2023 | 103.12% |
| Mar 31, 2023 | 266.75% |
| Dec 31, 2022 | 471.18% |
| Sep 30, 2022 | 111.98% |
| Jun 30, 2022 | 73.79% |
| Mar 31, 2022 | -227.32% |
| Dec 31, 2021 | 70.65% |
| Sep 30, 2021 | 4.62% |